SION — Sionna Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2036042 ·
Last close
$4.90
Market Cap
$221.24M
52W High
$54.97
52W Low
$4.01
ADV30
1,349,910
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -32,470,000 | -29,886,000 | 283,249,000 | 63,322,000 | 17,474,000 |
| Mar 2026 | 0 | — | -29,599,000 | -26,779,000 | 305,039,000 | 63,324,000 | 16,831,000 |
| Dec 2025 | 0 | — | -23,612,000 | -20,440,000 | 325,953,000 | 58,451,000 | 19,120,000 |
| Sep 2025 | 0 | — | -23,805,000 | -20,278,000 | 339,270,000 | 50,831,000 | 17,602,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-75,916,000
Investing CF
$91,979,000
Financing CF
$6,275,000
CapEx
$-377,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.18
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-313,019,000
Inventory
—
Receivables
—
ST Investments
$147,709,000
EBIT TTM
$-109,486,000
Pretax Income TTM
$-97,383,000
Interest Exp TTM
—
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -88,982,000 | -75,268,000 | 325,953,000 | 19,120,000 | 306,833,000 | -66,297,000 |
| Dec 2024 | 0 | -70,556,000 | -61,688,000 | 185,752,000 | 349,465,000 | -163,713,000 | -52,787,000 |
| Dec 2023 | 0 | -50,333,000 | -47,263,000 | 51,945,000 | 166,826,000 | -114,881,000 | -43,699,000 |
| Dec 2022 | 0 | -41,372,000 | -40,240,000 | 87,369,000 | 157,293,000 | -69,924,000 | -36,068,000 |
TTM Snapshot
Revenues TTM
$13,115,000
NetIncome TTM
$-85,565,000
OpCashFlow TTM
—
Assets (Latest)
$305,039,000
Forward EPS
$-2.52
Max Pain — expiry 2027-01-15
max pain strike: $7.50 · spot: $4.90 · call oi: 621 · put oi: 7,683
Expected Move to 2027-01-15:
±$2.70
(55.10%) —
implied range
$2.20 –
$7.60
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ADCT | ADC Therapeutics SA | $220.87M | $1.73 | — |
| TRDA | Entrada Therapeutics, Inc. | $220.77M | $5.67 | — |
| AKBA | Akebia Therapeutics, Inc. | $221.99M | $0.80 | — |
| NATR | NATURES SUNSHINE PRODUCTS INC | $222.41M | $12.64 | — |
| EVMN | Evommune, Inc. | $226.83M | $6.25 | — |
News headlines (Yahoo Finance, 1h cache)
Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference
2026-10-08 20:30 · Yahoo
Sionna Therapeutics (SION) Approves 46% Job Cut. Can a New Trial Make its Cash More Productive?
2026-09-17 21:21 · Yahoo
FDA clears first generic radioligand drug; Sionna turns to layoffs
2026-09-15 17:13 · Yahoo
Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial
2026-09-14 20:01 · Yahoo
Sionna Therapeutics (SION) Resets After Trial Miss, Is The Discount Now Too Deep?
2026-08-13 09:11 · Yahoo
Sionna Therapeutics (SION) Is Down 86.8% After Halting SION-719 And Refocusing Its CF Pipeline – Has The Bull Case Changed?
2026-08-13 05:13 · Yahoo
Sionna Therapeutics (SION) Stock Still Looks Cheap After The 90% Fall
2026-08-12 10:12 · Yahoo
Sionna Therapeutics stock falls 92% after SION-719 trial failure
2026-08-11 13:11 · Yahoo
Sionna Therapeutics (SION) Halts Lead Cystic Fibrosis Drug After Phase 2 Failure
2026-08-11 08:12 · Yahoo
SION Stock On Track For Worst Day Ever After 90% Drop — What’s Driving The Selloff?
2026-08-10 17:18 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.